Emerging glyco‐based strategies to steer immune responses. (15th May 2021)

• Record Type: Journal Article
• Authors: Anderluh, Marko; Berti, Francesco; Bzducha‐Wróbel, Anna; Chiodo, Fabrizio; Colombo, Cinzia; Compostella, Federica; Durlik, Katarzyna; Ferhati, Xhenti; Holmdahl, Rikard; Jovanovic, Dragana; Kaca, Wieslaw; Lay, Luigi; Marinovic‐Cincovic, Milena; Marradi, Marco; Ozil, Musa; Polito, Laura; Reina‐Martin, Josè Juan; Reis, Celso A.; Sackstein, Robert; Silipo, Alba; Švajger, Urban; Vaněk, Ondřej; Yamamoto, Fumiichiro; Richichi, Barbara; van Vliet, Sandra J.
• Is Part Of: FEBS journal. Volume 288:Number 16(2021)
• Page Start: 4746
• Page End: 4772
• Publication Date: 2021-05-15
• Subjects: autoimmunity -- cancer -- glycosylation -- immune system -- vaccination; Biochemistry -- Periodicals; Molecular biology -- Periodicals; Pathology, Molecular -- Periodicals; 572
• DOI: 10.1111/febs.15830
• Languages: English
• ISSNs: 1742-464X

Abstract

Abstract : Glycan structures are common posttranslational modifications of proteins, which serve multiple important structural roles (for instance in protein folding), but also are crucial participants in cell–cell communications and in the regulation of immune responses. Through the interaction with glycan‐binding receptors, glycans are able to affect the activation status of antigen‐presenting cells, leading either to induction of pro‐inflammatory responses or to suppression of immunity and instigation of immune tolerance. This unique feature of glycans has attracted the interest and spurred collaborations of glyco‐chemists and glyco‐immunologists to develop glycan‐based tools as potential therapeutic approaches in the fight against diseases such as cancer and autoimmune conditions. In this review, we highlight emerging advances in this field, and in particular, we discuss on how glycan‐modified conjugates or glycoengineered cells can be employed as targeting devices to direct tumor antigens to lectin receptors on antigen‐presenting cells, like dendritic cells. In addition, we address how glycan‐based nanoparticles can act as delivery platforms to enhance immune responses. Finally, we discuss some of the latest developments in glycan‐based therapies, including chimeric antigen receptor (CAR)‐T cells to achieve targeting of tumor‐associated glycan‐specific epitopes, as well as the use of glycan moieties to suppress ongoing immune responses, especially in the context of autoimmunity. Abstract : Glycans are macromolecules that perform crucial roles in development, in cell–cell communication, and in the regulation of immune responses. In this review, we highlight how glycans can be exploited and empowered as treatment or vaccine modalities, particularly in the fight against cancer and autoimmune diseases.